BCA
UTHR icon

Bray Capital Advisors’s United Therapeutics UTHR Stock Holding History

Bray Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-21
Closed -$3K – 299
2015
Q3 		$3K Hold
21
– – ﹤0.01% 380
2015
Q2 		$4K Buy
+21
New +$3.78K ﹤0.01% 398

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bray Capital Advisors's UTHR Position: Q4 2015 in Review

Bray Capital Advisors sold out of United Therapeutics (UTHR) in Q4 2015, closing a stake of 21 shares — an estimated $3K sold.

Bray Capital Advisors first reported a position in UTHR in Q2 2015 and held it in 2 quarters. The position peaked at $4K in Q2 2015. 386 funds tracked by Wall St. Rank hold UTHR as of Q4 2015.

  • Bray Capital Advisors reported no remaining United Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Bray Capital Advisors sold 21 United Therapeutics shares in Q4 2015, an estimated $3K.
  • Bray Capital Advisors first reported a position in United Therapeutics in Q2 2015 and held it in 2 quarters.
  • Bray Capital Advisors's United Therapeutics position peaked at $4K in Q2 2015.
  • 386 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2015.

Based on Bray Capital Advisors's 13F filing for Q4 2015, filed 1 Feb 2016.